Shaji K Kumar, MD
Avet-Loiseau H et al. Evaluation of minimal residual disease (MRD) by next generation sequencing (NGS) is highly predictive of progression free survival in the IFM/DFCI 2009 trial. Blood 2015;126(23):191. Abstract
Hillengass J et al. Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma. Haematologica 2012;97(11):1757-60. Abstract
Hillengass J et al. Diffusion-weighted imaging for non-invasive and quantitative monitoring of bone marrow infiltration in patients with monoclonal plasma cell disease: A comparative study with histology. Br J Haematol 2011;153(6):721-8. Abstract
Hoering A et al. Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols. Blood 2009;114(7):1299-305. Abstract
Kumar S et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016;17(8):e328-e346. Abstract
Martinez-Lopez J et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood 2014;123(20):3073-9. Abstract
Munshi NC et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv 2020;4(23):5988-99. Abstract
Munshi NC et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: A meta-analysis. JAMA Oncol 2017;3(1):28-35. Abstract
Nosàs-Garcia S et al. Dynamic contrast-enhanced MRI for assessing the disease activity of multiple myeloma: A comparative study with histology and clinical markers. J Magn Reson Imaging 2005;22(1):154-62. Abstract
Rawstron AC et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: Impact on outcome in the Medical Research Council Myeloma IX study. J Clin Oncol 2013;31(20):2540-7. Abstract
Philip A Thompson, MB, BS
Al-Sawaf O et al. Clonal dynamics after venetoclax-obinutuzumab therapy: Novel insights from the randomized, phase 3 CLL14 trial. ASH 2020;Abstract 127.
Al-Sawaf O et al. Fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Follow-up of efficacy and safety results from the multicenter, open-label, randomized phase 3 CLL14 trial. EHA 2020;Abstract S155.
Bottcher S et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: A multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 2012;30(9):980-8. Abstract
Dimier N et al. A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL. Blood 2018;131(9):955-62. Abstract
Kater AP et al. Five-year analysis of MURANOs study demonstrates enduring undetectable minimal residual disease (uMRD) in a subset of relapsed/refractory chronic lymphocytic leukemia (R/R CLL) patients (pts) following fixed-duration venetoclax-rituximab (VenR) therapy (tx). ASH 2020;Abstract 125.
Logan AC et al. Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia. Leukemia 2013;27(8):1659-65. Abstract
Rawstron AC et al. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: An European Research Initiative on CLL study. Leukemia 2016;30(4):929-36. Abstract
Thompson PA et al. Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. Leukemia 2018;32(11):2388-98. Abstract
Thompson PA, Wierda WG. Eliminating minimal residual disease as a therapeutic end point: Working toward cure for patients with CLL. Blood 2016;127(3):279-86. Abstract